Drugs · acquisition-cost intelligence
Truvada
emtricitabine and tenofovir disoproxil fumarate· ingredient emtricitabineAntivirals for treatment of HIV infections, combinations· EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1; EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1; EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.45084
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other emtricitabine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Emtricitabine and Tenofovir Disoproxil Fumarate | $10.19 | +$9.74 |
| Emtriva | $14.93 | +$14.47 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 53% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.